Extragonadal germ cell tumors in Taiwan

An analysis of treatment results of 59 patients

Yu Juei Hsu, Lu Pai, Yeu Chin Chen, Ching Liang Ho, Woei Yau Kao, Tsu Yi Chao

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

BACKGROUND. Extragonadal germ cell tumors (EGCT) are rare. They are biologically distinct from their testicular counterparts. Information regarding these tumors from the Far East is limited. More investigations are warranted to define the optimal treatment. METHODS. Retrospective review of the medical records of 59 patients with EGCT treated between 1983 and 2001 at a large, tertiary care institute in Taipei. RESULTS. The study population comprised 54 males and 5 females, ranging in age from 1 to 68 years old (median age, 21 years). Primary tumors occurred in the mediastinum (n = 27), retroperitoneum (n = 6), central nervous system (CNS; n = 24), and other sites (n = 2). Patients received surgery, chemotherapy, radiotherapy, or a combination of treatment modalities as the primary treatment. Three patients with mediastinal seminoma achieved complete remission (CR) and are alive with no evidence of disease (NED), with a median follow-up of 118 months. Of 24 patients with mediastinal nonseminomas, 8 (33%) are alive with a median disease-free survival (DFS) period of 33 months. Two of six patients with retroperitoneal nonseminomas obtained CR and are alive with NED at 41 and 110 months, respectively. Of 24 patients with intracranial germ cell tumors, 16 had germinoma and 13 (81%) achieved CR with NED at 8-228 months (median duration, 104 months). Four of eight patients with CNS nongerminomas remain in CR and are alive with a median DFS period of 48 months. Four patients with mediastinal nonsemonimas treated with salvage chemotherapy died. CONCLUSIONS. The treatment results of our patients with seminomatous EGCT are comparable to those of Western countries. However, the treatment results of patients with nonseminomatous EGCT are not as good. The reason for this discrepancy needs to be explored for a better treatment outcome of for patients in Taiwan with EGCT.

Original languageEnglish
Pages (from-to)766-774
Number of pages9
JournalCancer
Volume95
Issue number4
DOIs
Publication statusPublished - Aug 15 2002
Externally publishedYes

Fingerprint

Germ Cell and Embryonal Neoplasms
Taiwan
Therapeutics
Disease-Free Survival
Germinoma
Drug Therapy
Seminoma
Far East
Mediastinum
Tertiary Healthcare
Medical Records
Neoplasms
Radiotherapy
Central Nervous System

Keywords

  • Central nervous system
  • Extragonadal
  • Germ cell tumor
  • Mediastinum
  • Nonseminoma
  • Retroperitoneum
  • Seminoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Extragonadal germ cell tumors in Taiwan : An analysis of treatment results of 59 patients. / Hsu, Yu Juei; Pai, Lu; Chen, Yeu Chin; Ho, Ching Liang; Kao, Woei Yau; Chao, Tsu Yi.

In: Cancer, Vol. 95, No. 4, 15.08.2002, p. 766-774.

Research output: Contribution to journalArticle

Hsu, Yu Juei ; Pai, Lu ; Chen, Yeu Chin ; Ho, Ching Liang ; Kao, Woei Yau ; Chao, Tsu Yi. / Extragonadal germ cell tumors in Taiwan : An analysis of treatment results of 59 patients. In: Cancer. 2002 ; Vol. 95, No. 4. pp. 766-774.
@article{6d65221555c344368a992119f6ae9a32,
title = "Extragonadal germ cell tumors in Taiwan: An analysis of treatment results of 59 patients",
abstract = "BACKGROUND. Extragonadal germ cell tumors (EGCT) are rare. They are biologically distinct from their testicular counterparts. Information regarding these tumors from the Far East is limited. More investigations are warranted to define the optimal treatment. METHODS. Retrospective review of the medical records of 59 patients with EGCT treated between 1983 and 2001 at a large, tertiary care institute in Taipei. RESULTS. The study population comprised 54 males and 5 females, ranging in age from 1 to 68 years old (median age, 21 years). Primary tumors occurred in the mediastinum (n = 27), retroperitoneum (n = 6), central nervous system (CNS; n = 24), and other sites (n = 2). Patients received surgery, chemotherapy, radiotherapy, or a combination of treatment modalities as the primary treatment. Three patients with mediastinal seminoma achieved complete remission (CR) and are alive with no evidence of disease (NED), with a median follow-up of 118 months. Of 24 patients with mediastinal nonseminomas, 8 (33{\%}) are alive with a median disease-free survival (DFS) period of 33 months. Two of six patients with retroperitoneal nonseminomas obtained CR and are alive with NED at 41 and 110 months, respectively. Of 24 patients with intracranial germ cell tumors, 16 had germinoma and 13 (81{\%}) achieved CR with NED at 8-228 months (median duration, 104 months). Four of eight patients with CNS nongerminomas remain in CR and are alive with a median DFS period of 48 months. Four patients with mediastinal nonsemonimas treated with salvage chemotherapy died. CONCLUSIONS. The treatment results of our patients with seminomatous EGCT are comparable to those of Western countries. However, the treatment results of patients with nonseminomatous EGCT are not as good. The reason for this discrepancy needs to be explored for a better treatment outcome of for patients in Taiwan with EGCT.",
keywords = "Central nervous system, Extragonadal, Germ cell tumor, Mediastinum, Nonseminoma, Retroperitoneum, Seminoma",
author = "Hsu, {Yu Juei} and Lu Pai and Chen, {Yeu Chin} and Ho, {Ching Liang} and Kao, {Woei Yau} and Chao, {Tsu Yi}",
year = "2002",
month = "8",
day = "15",
doi = "10.1002/cncr.10738",
language = "English",
volume = "95",
pages = "766--774",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Extragonadal germ cell tumors in Taiwan

T2 - An analysis of treatment results of 59 patients

AU - Hsu, Yu Juei

AU - Pai, Lu

AU - Chen, Yeu Chin

AU - Ho, Ching Liang

AU - Kao, Woei Yau

AU - Chao, Tsu Yi

PY - 2002/8/15

Y1 - 2002/8/15

N2 - BACKGROUND. Extragonadal germ cell tumors (EGCT) are rare. They are biologically distinct from their testicular counterparts. Information regarding these tumors from the Far East is limited. More investigations are warranted to define the optimal treatment. METHODS. Retrospective review of the medical records of 59 patients with EGCT treated between 1983 and 2001 at a large, tertiary care institute in Taipei. RESULTS. The study population comprised 54 males and 5 females, ranging in age from 1 to 68 years old (median age, 21 years). Primary tumors occurred in the mediastinum (n = 27), retroperitoneum (n = 6), central nervous system (CNS; n = 24), and other sites (n = 2). Patients received surgery, chemotherapy, radiotherapy, or a combination of treatment modalities as the primary treatment. Three patients with mediastinal seminoma achieved complete remission (CR) and are alive with no evidence of disease (NED), with a median follow-up of 118 months. Of 24 patients with mediastinal nonseminomas, 8 (33%) are alive with a median disease-free survival (DFS) period of 33 months. Two of six patients with retroperitoneal nonseminomas obtained CR and are alive with NED at 41 and 110 months, respectively. Of 24 patients with intracranial germ cell tumors, 16 had germinoma and 13 (81%) achieved CR with NED at 8-228 months (median duration, 104 months). Four of eight patients with CNS nongerminomas remain in CR and are alive with a median DFS period of 48 months. Four patients with mediastinal nonsemonimas treated with salvage chemotherapy died. CONCLUSIONS. The treatment results of our patients with seminomatous EGCT are comparable to those of Western countries. However, the treatment results of patients with nonseminomatous EGCT are not as good. The reason for this discrepancy needs to be explored for a better treatment outcome of for patients in Taiwan with EGCT.

AB - BACKGROUND. Extragonadal germ cell tumors (EGCT) are rare. They are biologically distinct from their testicular counterparts. Information regarding these tumors from the Far East is limited. More investigations are warranted to define the optimal treatment. METHODS. Retrospective review of the medical records of 59 patients with EGCT treated between 1983 and 2001 at a large, tertiary care institute in Taipei. RESULTS. The study population comprised 54 males and 5 females, ranging in age from 1 to 68 years old (median age, 21 years). Primary tumors occurred in the mediastinum (n = 27), retroperitoneum (n = 6), central nervous system (CNS; n = 24), and other sites (n = 2). Patients received surgery, chemotherapy, radiotherapy, or a combination of treatment modalities as the primary treatment. Three patients with mediastinal seminoma achieved complete remission (CR) and are alive with no evidence of disease (NED), with a median follow-up of 118 months. Of 24 patients with mediastinal nonseminomas, 8 (33%) are alive with a median disease-free survival (DFS) period of 33 months. Two of six patients with retroperitoneal nonseminomas obtained CR and are alive with NED at 41 and 110 months, respectively. Of 24 patients with intracranial germ cell tumors, 16 had germinoma and 13 (81%) achieved CR with NED at 8-228 months (median duration, 104 months). Four of eight patients with CNS nongerminomas remain in CR and are alive with a median DFS period of 48 months. Four patients with mediastinal nonsemonimas treated with salvage chemotherapy died. CONCLUSIONS. The treatment results of our patients with seminomatous EGCT are comparable to those of Western countries. However, the treatment results of patients with nonseminomatous EGCT are not as good. The reason for this discrepancy needs to be explored for a better treatment outcome of for patients in Taiwan with EGCT.

KW - Central nervous system

KW - Extragonadal

KW - Germ cell tumor

KW - Mediastinum

KW - Nonseminoma

KW - Retroperitoneum

KW - Seminoma

UR - http://www.scopus.com/inward/record.url?scp=0037102942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037102942&partnerID=8YFLogxK

U2 - 10.1002/cncr.10738

DO - 10.1002/cncr.10738

M3 - Article

VL - 95

SP - 766

EP - 774

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -